

# Pharmacy BULLETIN BOARD

Industry Issue ■ Monday February 9, 2015

Odan Laboratories is pleased to announce the launch of a brand new product:

## ODAN POLYSACCHARIDE Iron Complex 150

Format	McKesson	K&F	PJC	Procurity	VDM	Nu-Quest
30 capsules	076403	151386	758792	211842	913525	POLY112ODA
100 capsules	076404	151371	758794	215503	913657	POLY113ODA

Odan Polysaccharide Iron Complex 150\*, containing 150 mg of elemental iron, is indicated for the treatment of iron deficient anemia.

### GENERIC EQUIVALENT TO FERAMAX 150†

To order, please contact your wholesaler or contact Odan directly by phone at 1-800-387-9342 or by e-mail at [info@odanlab.com](mailto:info@odanlab.com).



\*Odan Polysaccharide Iron Complex 150 is a trademark of Odan Laboratories Ltd.  
†FeraMax is a registered trademark of BioSynt Inc

## FROM THE NEWSWIRE

**DORVAL, QC:** Quebec patients living with COPD now have access to Ultibro® Breezhaler® with its addition to the list of medications of the Régie de l'assurance maladie du Québec (RAMQ) as "Médicament d'exception" for the treatment of patients with COPD whose symptoms are not adequately controlled after a three month trial with a long acting bronchodilator. The Quebec government has become the first public payer in Canada to reimburse Ultibro® Breezhaler®. It is available in pharmacies province-wide.

**ROCHESTER, N.Y.:** Koning Corporation, a leading developer of advanced medical imaging systems has announced that the FDA has approved their Koning Breast CT (KBCT) system and KBCT-guided biopsy bracket. This approval signals that KBCT has undergone and successfully completed all aspects of FDA's rigorous Pre- Market Approval (PMA) process for medical devices to include extensive clinical study. KBCT is intended to provide three-dimensional (3D) images for diagnostic imaging of the breast.



Lower Cost Generic Alternative to Pennsaid®1!!!

### P<sup>r</sup>Taro-Diclofenac

Diclofenac Sodium Topical Solution 1.5%

**Taro-Diclofenac Topical Solution 1.5%** is Available for Immediate Shipping!!!

- Bioequivalent to Pennsaid®1
- Interchangeable with Pennsaid (OFI) in Ontario
- High Quality, Lower Price Alternative

### Topical Solution 1.5%

DIN	Size	UPC	Wholesaler			
			McKesson	K&F	Procurity	McMahon
02420988	2 x 60 mL	063691073517	060770	147411	256323	10071421
	150 mL	063691073548	060771	147409	256480	10071400

For more information, or to place an order for **Taro-Diclofenac** topical solution, please contact your Taro Representative, your wholesaler, our Customer Service department at **1-800-268-1975** or visit our Website at [www.taro.ca](http://www.taro.ca).

<sup>1</sup>Data on file, Taro Pharmaceuticals Inc.

<sup>2P</sup>Taro-Diclofenac Product Monograph.

<sup>®</sup>Pennsaid is a registered trademark of Nuvo Research Inc.

TARO is a registered trademark of Taro Pharmaceuticals Inc.

**TORONTO:** Merck, known as MSD outside the United States and Canada, has confirmed its commitment to research and innovation by contributing a total of \$7.5 million to the Structural Genomics Consortium (SGC) Toronto and its network, thereby becoming a member of the consortium.

**MISSISSAUGA, ON:** What a difference the years make. There was a time when a breast cancer diagnosis meant that surgery followed by radiation was a woman's only hope of fighting her cancer. This is because breast cancer was once commonly viewed as a single disease, requiring one treatment approach. This singular approach to treating breast cancer often resulted in tough-to-manage side effects such as severe nausea, exhaustion, bone marrow toxicity and lengthy recoveries that made the treatments difficult treatments for many women to tolerate. Over the past 30+ years, there have been major advancements that have changed a woman's experience with breast cancer. For example, the improved understanding of how hor-mones affect the growth of cancer cells led to the development of treatments for hormone-sensitive breast cancer.



**Now listed on the List of Medications in Quebec!!!**

**◆ Taro-Testosterone**

Testosterone Undecanoate Capsules 40 mg

- Bioequivalent and Interchangeable with Andriol®<sup>1</sup>
- High Quality, Lower Price Alternative
- Androgen; testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone<sup>2</sup>

**DIN: 02421186**

Size	UPC	Wholesaler			
		McKesson	K&F	Procurity	McMahon
60	063691075252	071138	149748	010324	10074980
120	063691073333	071136	149837	009946	10075001

For further information, or to place an order for ◆Taro-Testosterone, please contact your Taro Representative, your wholesaler, our Customer Service department at **1-800-268-1975**, or visit our Website at **www.taro.ca**.

<sup>1</sup>Data on file, Taro Pharmaceuticals Inc.

<sup>2</sup>◆Taro-Testosterone Product Monograph.

®Registered Trademark of N.V. Organon. Used under license. TARO is a registered trademark of Taro Pharmaceuticals Inc.

**OTTAWA:** Since the first notification at the end of March 2013, China has been reporting to the World Health Organization (WHO) confirmed cases of a type of avian influenza virus in humans identified as A(H7N9). Most cases develop severe pneumonia and breathing difficulties with some resulting in death.

**OTTAWA:** Canada's Chief Public Health Officer, Dr. Gregory Taylor and Dr. Bonnie Henry, British Columbia's Deputy Provincial Health Officer have confirmed that the second individual in B.C. has now tested positive for the H7N9 avian influenza strain. As noted by health officials on January 26th, the husband and wife recently returned to Canada from China.

**WINNIPEG:** The Honourable Rona Ambrose, Minister of Health, and Canada's Chief Public Health Officer, Dr. Gregory Taylor, have announced that one of the Public Health Agency of Canada's mobile laboratory teams in Sierra Leone is returning to Canada after successfully concluding its mission working with Doctors Without Borders on the Ebola outbreak response.

**OTTAWA:** The Government of Canada has published the results of the 2013 Canadian Tobacco, Alcohol, and Drugs Survey (CTADS), which demonstrate progress made in sustaining all-time lows in smoking rates, while also highlighting the need for continued attention to issues such as marijuana use among youth and prescription drug abuse.

**OTTAWA:** Health Canada is reminding Canadians about the risks of purchasing unlicensed home-use diagnostic test kits following recent compliance and enforcement actions undertaken by the Department.

**To include your communication in the next issue,  
please contact: Health Response**

T: 416-863-5403 | F: 416-863-9620 |  
[hrc@healthresponse.ca](mailto:hrc@healthresponse.ca)

**Next Issue: Monday February 23<sup>rd</sup>, 2015**  
Deadline: Thursday February 19<sup>th</sup>, 2015